ArticleNature communications2020
An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 68 citations in OpenAlex.
- Nestin and osteocrin mRNA increases in human semitendinosus myotendinous junction 7 days after a single bout of eccentric exercise.Histochemistry and cell biology · 2022Trial
- Generation of antifungals to combat drug resistance using language models and diffusion models.Journal of advanced research · 2026Article
- Review
- Genomic Analysis Reveals Diversified and Stress-Responsive Transport Repertoire inJournal of fungi (Basel, Switzerland) · 2026Article
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- In silico identification of sclerostin inhibitors.Molecular diversity · 2026Article
- Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection.Journal of invertebrate pathology · 2026Article
- Relative contributions of the ERG11Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026Article
- Growth phase influences virulence inmSphere · 2025Article
- A systematic comparison of CRISPR-Cas9 allele editing in Candida auris demonstrates unreliable cassette integration and effective episomal plasmid-based editing.Scientific reports · 2025Article
- Connecting chemical structure to single cell signaling profiles.Communications biology · 2025Article
- A cationic amphiphilic drug synergizes with strobilurin fungicides to control fungal-borne plant diseases.Cell chemical biology · 2025Article
- Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update.Microorganisms · 2025Review
- Developing the trehalose biosynthesis pathway as an antifungal drug target.npj antimicrobials and resistance · 2025Review
- A comparative evaluation of CRISPR-Cas9 allele editing systems inbioRxiv : the preprint server for biology · 2025Article
- Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistantEmerging microbes & infections · 2024Article
- Interdisciplinary approaches for the discovery of novel antifungals.Trends in molecular medicine · 2024Review
- A chemical screen identifies structurally diverse metal chelators with activity against the fungal pathogenMicrobiology spectrum · 2024Article
- The anti-inflammatory and immunological properties of SGLT-2 inhibitors.Journal of endocrinological investigation · 2023Review
- Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.Thoracic cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
Abstract
Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of C. auris.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.